Search results for "Drug-resistance"

showing 4 items of 4 documents

Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia

2020

N.J.S. is partially funded by the Department of Veterans Affairs, Quality Enhancement Research Initiative (QUERI) Partnered Evaluation Initiative Grant (HX002263-01A1). Background and objective : Enterobacteriaceae (EB) spp. family is known to include potentially multidrug-resistant (MDR) microorganisms, and remains as an important cause of community-acquired pneumonia (CAP) associated with high mortality. The aim of this study was to determine the prevalence and specific risk factors associated with EB and MDR-EB in a cohort of hospitalized adults with CAP. Methods : We performed a multinational, point-prevalence study of adult patients hospitalized with CAP. MDR-EB was defined when ≥3 ant…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtycommunity-acquired pneumoniaCommunity-acquired pneumoniaEnterobacteriaceae ; community-acquired pneumonia ; multidrug-resistance ; prevalence ; risk factorsInternational CooperationprevalenceMultidrug-resistanceMicrobial Sensitivity TestsSettore MED/10 - Malattie Dell'Apparato RespiratorioResearch initiativeE-NDASCohort StudiesCommunity-acquired pneumoniaSDG 3 - Good Health and Well-beingEnterobacteriaceaePrevalenceHumansMedicinerisk factorsIn patientRisk factorVeterans Affairshealth care economics and organizationsAgedbusiness.industryEnterobacteriaceae InfectionsQR Microbiologymedicine.diseasecommunity-acquired pneumonia; Enterobacteriaceae; multidrug-resistance; prevalence; risk factorsmultidrug-resistanceDrug Resistance MultiplehumanitiesQuality enhancementQRCommunity-Acquired InfectionsHospitalizationRisk factorsrisk factorFamily medicineFemalebusinessRisk assessmentCohort study
researchProduct

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

2014

Background: One out of ten newly diagnosed patients in Europe was infected with a virus carrying a drug resistant mutation. We analysed the patterns over time for transmitted drug resistance mutations (TDRM) using data from the European Spread program.Methods: Clinical, epidemiological and virological data from 4317 patients newly diagnosed with HIV-1 infection between 2002 and 2007 were analysed. Patients were enrolled using a pre-defined sampling strategy.Results: The overall prevalence of TDRM in this period was 8.9% (95% CI: 8.1-9.8). Interestingly, significant changes over time in TDRM caused by the different drug classes were found. Whereas nucleoside resistance mutations remained con…

Malevirus strainResistanceHIV InfectionsDrug resistanceTHERAPYNucleoside Reverse Transcriptase InhibitorANTIRETROVIRAL DRUG-RESISTANCE0302 clinical medicineMedical microbiologyGenotypeMedicine and Health SciencesPrevalenceHIV Infection030212 general & internal medicineUNITED-KINGDOMPhylogeny0303 health sciencesCommunicable diseaseTransmission (medicine)adultvirus mutationUPDATED RECOMMENDATIONSvirus transmission3. Good healthEuropeInfectious Diseasesfemalerisk factorvirus resistanceFemaleNAIVE PATIENTSSOCIETY-USA PANELResearch ArticleHumanAdultmedicine.medical_specialtyGenotypeAnti-HIV AgentsVirusArticle03 medical and health sciencesSDG 3 - Good Health and Well-beingmaleMOLECULAR EPIDEMIOLOGYDrug Resistance Viralmedicineproteinase inhibitorHumansTransmissioncontrolled studyhumanmolecular phylogeny030304 developmental biologynonhumanMUTATIONSbusiness.industryAnti-HIV Agentnucleotide sequencenonnucleoside reverse transcriptase inhibitorHuman immunodeficiency virus 1 infectionVirologymajor clinical studyunindexed sequenceParasitology3121 General medicine internal medicine and other clinical medicineMutationHIV-1business
researchProduct

Efficacy of levetiracetam in the treatment of drug-resistant Rett Syndrome.

2010

Rett syndrome (RTT) is a progressive neurological disorder characterized by a wide spectrum of phenotypes. Epilepsy is reported to occur in 50–90% of patients with RTT; some develop medically refractory epilepsy. The aim of this study is to investigate the efficacy of levetiracetam (LEV) in drug-resistant patients with RTT. This prospective, pragmatic, open-label study consisted of an 8-week baseline period and a 6-month evaluation period. Efficacy variable was the mean frequency of monthly seizures before, and after 3 and 6 months of treatment with LEV. Eight female patients, aged 7.5–19 years (M12.8 ± 5) entered the study. Mean age at epilepsy onset was 25.8 ± 14.1 months. All patients sh…

Pediatricsmedicine.medical_specialtyLevetiracetamAdolescentMethyl-CpG-Binding Protein 2medicine.medical_treatmentRett syndromeNeurological disorderDrug Administration ScheduleCentral nervous system diseasedrug therapy/geneticsYoung AdultEpilepsyanalogs /&/ derivatives/therapeutic useSeizuresConvulsionmedicineRett SyndromeHumansgeneticsEEGProspective StudiesMyoclonic seizuresChildProspective cohort studyPsychiatryDrug-resistanceAnalysis of Variancebusiness.industryPatient SelectionFocal seizureElectroencephalographymedicine.diseaseAdolescent Analysis of Variance Anticonvulsants; therapeutic use Child Drug Administration Schedule Electroencephalography Female Humans Methyl-CpG-Binding Protein 2; genetics Patient Selection Piracetam; analogs /&/ derivatives/therapeutic use Prospective Studies Quality of Life Rett Syndrome; drug therapy/genetics Seizures; drug therapy/genetics Treatment Outcome Young AdultPiracetamSettore MED/39 - Neuropsichiatria InfantileTreatment OutcomeAnticonvulsantNeurologytherapeutic useQuality of LifeAnticonvulsantsFemaleNeurology (clinical)Levetiracetammedicine.symptombusinessmedicine.drug
researchProduct

The role of circulating and exosomal miRNAs as biomarkers of drug-resistant epilepsy

Epilepsy is estimated to affect about 65 million individuals worldwide, with up to 30 percent of drug-resistant patients who do not have remission despite appropriate therapy with antiepileptic drugs (AEDs). Therefore, it is important to distinguish drug-resistant epilepsy early in the course of disease to start a specific therapeutical approach as soon as possible. Recently circulating miRNAs have been proposed as promising biomarkers for different neurodegenerative disorders, including epilepsy. MiRNAs are a class of small non-coding RNA that regulate gene expression at a post-transcriptional level. The regulatory mechanisms controlling translation of mRNA transcripts represents to date a…

temporal lobe epilepsy drug-resistance miRNAsSettore MED/26 - Neurologia
researchProduct